Speaker: 

Tristan Maiers, PharmD, BCOP, PGY2 Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: - 

•Describe the mechanism of action of tarlatamab and its role in targeting DLL3-expressing small cell lung cancer (SCLC).
•Evaluate the clinical efficacy and safety data from key trials supporting the use of tarlatamab in extensive-stage SCLC.
•Apply knowledge of tarlatamab’s dosing strategy, monitoring requirements, and management of adverse events in clinical practice.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP, Rajiv Panikkar, MD, Michele Long, BSN, Jaime Weeder, NP, Christopher Kashi, PA, and Celeste Vanhorn, CphT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None

Session date: 
10/21/2025 - 7:00am to 8:00am EDT
Location: 
Virtual via Microsoft Teams
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE
  • 1.00 ACPE Tech
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation Credit
Please login or register to take this course.